flt3/btk

BTK-IN-24 是一种布鲁顿酪氨酸激酶 （BTK）抑制剂，具有潜在的抗癌活性，可用于研究骨髓增生性疾病。

RSH-7 是一种高效的 BTK 和 FLT3 双重抑制剂，IC50 分别为 47、12 nM。RSH-7 具有抗增殖活性和抗肿瘤活性，可诱导细胞凋亡 (apoptosis) ，抑制 BTK 和 FLT3 信号转导。

AZ7550 是 AZD9291 的活性代谢物，可抑制 IGF1R 活性，IC50为 1.6 μM。

AZ7550 hydrochloride (AZ7550 hydrochloride ) 是 AZD9291 的活性代谢物，可抑制 IGF1R 活性，IC50为 1.6 μM。

AZ7550 trimesylate salt (AZ7550 Mesylate) 是奥希替尼的活性代谢产物，AZ7550 trimesylate salt 抑制 IGF1R 活性，可用于研究非小细胞肺癌。

JAK3-IN-1 是一种具有口服活性、选择性和高效性的 JAK3 抑制剂，可用于研究免疫系统疾病。

TL12-186 是一种依赖于 Cereblon 的激酶降解剂，可降解 CDK，BTK，FLT3，Aurora 等激酶。TL12-186 对 CDK2 cyclin A 和 CDK9 cyclin T1 有抑制作用，IC50 分别为 73 和 55 nM。

Luxeptinib (CG-806) is a novel pan-FLT3 pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4].

Abivertinib, also known as AC0010 and Avitinib, is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor that demonstrated clinical efficacy and manageable adverse events (AEs). Abivertinib inhibits cell proliferation, reduces colony-forming capacity, and induces apoptosis and cell cycle arrest in AML cells, especially those harboring FLT3-ITD mutations. Abivertinib was also found to be more sensitive than ibrutinib in treating AML. Abivertinib may be a promising novel agent for AML, with potential for combination treatment with HHT.